Background: In nonresectable glioblastoma (GBM), stereotactic biopsies are performed to retrieve tissue for diagnostic purposes. The analysis of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation adds prognostic and predictive information. Objectives: The aim of the study was to detect confounding factors that limit the number of conclusive MGMT promoter methylation results. Methods: We analyzed 71 consecutive GBM patients undergoing stereotactic biopsy on whom MGMT analysis was performed by methylation-specific polymerase chain reaction. Specimens were correlated to imaging by coregistration and prospective documentation of biopsy localization. Our findings were validated in an additional 62 GBM stereotactic biopsies. Results: Our results demonstrate that the best MGMT promoter methylation results were obtained from samples (n = 71) taken in a tangential manner from tumor areas showing contrast enhancement in magnetic resonance imaging. In the additional validation series of 62 stereotactically biopsied GBM, we were able to increase the rate of conclusive MGMT promoter methylation results from 76.1 to 85.48% by strictly planning the route of biopsy in a tangential manner if possible. Conclusions: These results underline that within the contrast-enhanced tumor part, choosing the trajectory in a tangential manner increases the diagnostic yield for conclusive MGMT promoter methylation analyses in stereotactic biopsies as a basis for patient stratification and individualized therapy.

1.
Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-489.
2.
Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3.
Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M: Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 2010;120:585-592.
4.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
5.
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-715.
6.
Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, Diaz LA Jr: Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol 2012;110:279-285.
7.
Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA: Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007;121:2458-2464.
8.
Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, Belka C, Kretzschmar HA, Tonn JC, Kreth FW: Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry 2011;82:441-446.
9.
Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M: Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One 2012;7:e33449.
10.
Owen CM, Linskey ME: Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive and negative predictive values of blood through the needle. J Neurooncol 2009;93:139-149.
11.
Tilgner J, Herr M, Ostertag C, Volk B: Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis - influence of clinical factors. Neurosurgery 2005;56:257-265, discussion 257-265.
12.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): WHO classification of tumors of the central nervous system. Lyon, IARC, 2007.
13.
Kreth FW, Warnke PC, Scheremet R, Ostertag CB: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762-766.
14.
Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T; ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62:564-576.
15.
Stummer W, van den Bent MJ, Westphal M: Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011;153:1211-1218.
16.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
17.
Smith JS, Quiñones-Hinojosa A, Barbaro NM, McDermott MW: Frame-based stereotactic biopsy remains an important diagnostic tool with distinct advantages over frameless stereotactic biopsy. J Neurooncol 2005;73:173-179.
18.
Aker FV, Hakan T, Karadereler S, Erkan M: Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimens. Neuropathology 2005;25:207-213.
19.
Shastri-Hurst N, Tsegaye M, Robson DK, Lowe JS, Macarthur DC: Stereotactic brain biopsy: an audit of sampling reliability in a clinical case series. Br J Neurosurg 2006;20:222-226.
20.
Weise LM, Bruder M, Eibach S, Seifert V, Byhahn C, Marquardt G, Setzer M: Efficacy and safety of local versus general anesthesia in stereotactic biopsies: a matched-pairs cohort study. J Neurosurg Anesthesiol 2013;25:148-153.
21.
Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK: Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol 2006;23:71-75.
22.
Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, Tonn JC, Kretzschmar HA, Kreth FW: Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol 2009;68:1219-1228.
23.
Chandrasoma PT, Smith MM, Apuzzo ML: Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery 1989;24:160-165.
24.
Feiden W, Steude U, Bise K, Gündisch O: Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings in biopsy cylinders and resected tumor tissue. Neurosurg Rev 1991;14:51-56.
25.
Glantz MJ, Burger PC, Herndon JE 2nd, Friedman AH, Cairncross JG, Vick NA, Schold SC Jr: Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 1991;41:1741-1744.
26.
Hemm S, Rigau V, Chevalier J, Picot MC, Bauchet L, El Fertit H, Rodriguez MA, Cif L, Vayssière N, Zanca M, Baldet P, Segnarbieux F, Coubes P: Stereotactic coregistration of 201Tl SPECT and MRI applied to brain tumor biopsies. J Nucl Med 2005;46:1151-1157.
27.
Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H: Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 2008;86:300-307.
28.
Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M: Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 2004;101:476-483.
29.
Wagner M, Nafe R, Jurcoane A, Pilatus U, Franz K, Rieger J, Steinbach JP, Hattingen E: Heterogeneity in malignant gliomas: a magnetic resonance analysis of spatial distribution of metabolite changes and regional blood volume. J Neurooncol 2011;103:663-672.
30.
Apuzzo ML, Chandrasoma PT, Cohen D, Zee CS, Zelman V: Computed imaging stereotaxy: experience and perspective related to 500 procedures applied to brain masses. Neurosurgery 1987;20:930-937.
31.
Lunsford LD, Martinez AJ: Stereotactic exploration of the brain in the era of computed tomography. Surg Neurol 1984;22:222-230.
32.
Ostertag CB, Mennel HD, Kiessling M: Stereotactic biopsy of brain tumors. Surg Neurol 1980;14:275-283.
33.
Ranjan A, Rajshekhar V, Joseph T, Chandy MJ, Chandi SM: Nondiagnostic CT-guided stereotactic biopsies in a series of 407 cases: influence of CT morphology and operator experience. J Neurosurg 1993;79:839-844.
34.
O'Neill KS, Dyer PV, Bell BA, Wilkins PR, Uttley D, Marsh HT: Is peroperative smear cytology necessary for CT-guided stereotaxic biopsy? Br J Neurosurg 1992;6:421-427.
35.
Sharma MC, Singh A, Verma A, Gaikwad S, Sarkar C: Diagnostic yield in computed tomography guided stereotactic biopsies. J Assoc Physicians India 1998;46:427-430.
36.
Ulm AJ, Bova FJ, Friedman WA: Stereotactic biopsy aided by a computer graphics workstation: experience with 200 consecutive cases. Surg Neurol 2001;56:366-371, discussion 371-372.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.